Cooper - COO STOCK NEWS

CooperCompanies has appointed Barbara Carbone as an independent director to its Board of Directors, effective May 1, 2025. Carbone will also serve on the Audit Committee.

With nearly 40 years of experience, Carbone spent most of her career at KPMG (1981-2019), serving 24+ years as an Audit Partner. Her notable roles included Chairperson of the KPMG Partnership Audit Committee and National Partner in Charge for Human Resources. She also served on the KPMG Retired Partners Council from 2019-2022.

Currently, Carbone serves as Board Chairperson at TrueCar and holds board positions at Limoneira Company and Bob's Discount Furniture. She holds a B.S. in Business Administration from California State University at Sacramento. Bob Weiss, Chairman of CooperCompanies, welcomed her expertise in finance, accounting, leadership, and HR.

CooperCompanies (Nasdaq: COO) has scheduled its second quarter 2025 financial results announcement for Thursday, May 29, 2025, at 4:15 PM ET. The medical device company will follow the release with a conference call at 5:00 PM ET to discuss financial performance and corporate developments.

Interested parties can join the call using the following details:

• Dial-in number: 800-715-9871
• Conference ID: 1515103

An audio webcast will be available simultaneously, and a replay can be accessed through the company's investor relations website at http://investor.coopercos.com.

CooperSurgical (NYSE: COO) has joined The Wyatt Foundation and The Conceive Fertility Foundation's 2025 IVF grant program as a new partner. The program will award $15,000 grants to five recipients who need IVF treatment to build their families.

CooperSurgical will provide an additional $1,000 per recipient for preimplantation genetic testing (PGT) with ICSI. Grant recipients can choose their preferred clinic, with those selecting a Prelude Network clinic receiving a 10% discount on fertility services.

The program launches during National Infertility Awareness Week (April 20-26, 2025), with applications open from April 21 to June 23, 2025. Recipients will be announced on July 1, 2025. Applicants must demonstrate financial need and provide a formal infertility diagnosis to be considered.

CooperCompanies (COO) reported strong Q1 2025 financial results with revenue increasing 4% year-over-year to $964.7 million. The company's two main segments showed growth: CooperVision revenue up 4% to $646.1 million and CooperSurgical revenue up 3% to $318.6 million.

Key financial metrics include:

• GAAP diluted EPS of $0.52, up $0.11 from last year
• Non-GAAP diluted EPS of $0.92, up $0.07
• Gross margin improved to 68% from 67%
• Operating margin increased to 19% from 16%
• Free cash flow of $101.2 million

The company updated its FY2025 guidance, projecting total revenue of $4,080 - $4,158 million (6-8% organic growth) and raised its non-GAAP diluted EPS guidance to $3.94 - $4.02.

CooperCompanies (Nasdaq: COO) has announced it will release its first quarter 2025 financial results on Thursday, March 6, 2025, at 4:15 PM ET. The company will host a conference call at 5:00 PM ET on the same day to discuss the results and current corporate developments. Investors can join the call using the dial-in number 800-715-9871 with conference ID 7466264. An audio webcast and replay will be available on the company's investor relations website.

CooperCompanies (NYSE: COO), a prominent medical device company, has announced its participation in the upcoming J.P. Morgan Healthcare Conference. The company's presentation is scheduled for Tuesday, January 14, 2025, at 6:00 PM ET. Al White, President and CEO, will be representing CooperCompanies at the conference. Interested parties can access both live and archived webcasts of the presentation through the company's investor relations website at http://investor.coopercos.com.

CooperCompanies (COO) reported strong financial results for Q4 and full year 2024. Q4 revenue reached $1,018.4 million, up 10% (7% organically), while fiscal year 2024 revenue hit $3.9 billion, up 8% organically. Q4 GAAP EPS increased 38% to $0.58, and non-GAAP EPS rose 19% to $1.04.

The company achieved record consolidated revenues, with strong performance in both CooperVision and CooperSurgical divisions. Q4 gross margin improved to 67% from 65% last year, while operating margin increased to 19% from 15%. For fiscal 2025, Cooper projects revenue of $4.08-4.16 billion with organic growth of 6-8%, and non-GAAP EPS guidance of $3.92-4.02.

CooperCompanies (Nasdaq: COO) has scheduled its fourth quarter and full year 2024 financial results announcement for Thursday, December 5, 2024, at 4:15 PM ET. The company will hold a conference call at 5:00 PM ET to discuss results and corporate developments. Interested parties can join via phone at 800-715-9871 using conference ID 2026064, or access the audio webcast through the investor relations website.

The Canadian Association of Optometrists (CAO) has launched a national campaign for Children Vision Month in October to raise awareness about myopia and the importance of annual eye exams for children. Myopia, affecting 30% of the population, is expected to increase to 50% by 2050. The campaign, supported by provincial optometrist associations and industry sponsors, aims to debunk myths and encourage early detection.

Key points:

• Myopia is a leading cause of vision loss globally
• Increased screen time is correlated with higher rates of myopia in children
• CAO recommends annual eye exams for children from 6-9 months to 19 years old
• Outdoor time may help delay myopia onset
• Limiting screen time and taking regular breaks are recommended

The campaign will run on various social media platforms throughout October, providing resources for parents to find local optometrists and take proactive steps for their children's eye health.